Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RaQualia Pharma Inc. ( (JP:4579) ) just unveiled an update.
RaQualia Pharma Inc. reported a decrease in net sales by 2.5% for the first nine months of 2025 compared to the same period in 2024, with a net loss of 568 million yen. Despite the decline in sales and profitability, the company maintained a strong equity ratio of 63.0% as of September 2025, indicating a stable financial position. The company has not announced any changes to its dividend forecasts, and it plans to hold a financial results briefing via webcast, reflecting its commitment to transparency with stakeholders.
The most recent analyst rating on (JP:4579) stock is a Hold with a Yen545.00 price target. To see the full list of analyst forecasts on RaQualia Pharma Inc. stock, see the JP:4579 Stock Forecast page.
More about RaQualia Pharma Inc.
RaQualia Pharma Inc. is a pharmaceutical company listed on the Tokyo Stock Exchange, focusing on the development and commercialization of innovative drug therapies. The company is involved in the pharmaceutical industry and aims to address unmet medical needs through its research and development efforts.
Average Trading Volume: 193,245
Technical Sentiment Signal: Sell
Current Market Cap: Yen12.72B
Learn more about 4579 stock on TipRanks’ Stock Analysis page.